Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -61.53% is 29% below its 1-year average of -47.53%, near the low end of its 1-year range (-61.53%–-33.53%).
As of the fiscal period ended Wednesday, December 31, 2025. 29.46% below its 12-month average of -47.53%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.97%.
RETURN ON ASSETS (ROA)
-61.53%
RETURN ON ASSETS (ROA) AVG TTM
-47.53%
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-29.46%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-90.85%
vs the sector median at left
Generate Biomedicines, Inc.
Market Cap
$1.77B
Return on Assets (ROA)
-61.53%
TTM Avg
-47.53%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.75B
Return on Assets (ROA)
-1.10%
TTM Avg
-1.54%
3Y Avg
-1.02%
5Y Avg
-1.23%
Market Cap
$1.74B
Return on Assets (ROA)
-18.68%
TTM Avg
-15.27%
3Y Avg
-14.09%
5Y Avg
-9.93%
Market Cap
$1.74B
Return on Assets (ROA)
-45.02%
TTM Avg
-50.76%
3Y Avg
-46.27%
5Y Avg
-37.50%
Market Cap
$1.80B
Return on Assets (ROA)
-22.53%
TTM Avg
-17.47%
3Y Avg
-13.86%
5Y Avg
-9.24%
Market Cap
$1.74B
Return on Assets (ROA)
3.18%
TTM Avg
-8.22%
3Y Avg
-16.26%
5Y Avg
-17.13%
Market Cap
$1.81B
Return on Assets (ROA)
10.25%
TTM Avg
8.68%
3Y Avg
8.17%
5Y Avg
8.38%
Market Cap
$1.73B
Return on Assets (ROA)
-4.17%
TTM Avg
-8.41%
3Y Avg
-15.90%
5Y Avg
-26.87%
Market Cap
$1.73B
Return on Assets (ROA)
-46.66%
TTM Avg
-46.30%
3Y Avg
-40.19%
5Y Avg
-33.55%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Generate Biomedicines, Inc. (GENB) | $1.77B | -61.53% | -47.53% | N/A | N/A |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | -1.10% | -1.54% | -1.02% | -1.23% |
| Novocure Ltd (NVCR)vs › | $1.74B | -18.68% | -15.27% | -14.09% | -9.93% |
| Absci Corporation (ABSI)vs › | $1.74B | -45.02% | -50.76% | -46.27% | -37.50% |
| Xencor, Inc. (XNCR)vs › | $1.80B | -22.53% | -17.47% | -13.86% | -9.24% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | 3.18% | -8.22% | -16.26% | -17.13% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.81B | 10.25% | 8.68% | 8.17% | 8.38% |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.73B | -4.17% | -8.41% | -15.90% | -26.87% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | -46.66% | -46.30% | -40.19% | -33.55% |
| Azenta, Inc. (AZTA)vs › | $1.81B | -6.55% | -5.28% | -5.65% | -2.06% |
ROA
-61.5%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -61.53% |
| 2024-12-31 | -33.53% |
